Target intelligence / Profile preview

Cysteine-S-conjugate beta-lyase

Molecular classification
Enzyme, Lyase, Pyridoxal phosphate enzyme, Carbon-sulfur lyase
01

Overview

Cysteine conjugate β-lyase is an enzyme activity found in various pyridoxal 5′-phosphate-dependent enzymes that can catalyze β-elimination of cysteine S-conjugates and selenocysteine Se-conjugates, generating reactive sulfur- or selenium-containing fragments, ammonia, and pyruvate[1][2][3][4]. In mammals, this activity is often not physiologically intended, but arises as a side reaction in aminotransferases and related enzymes[2][3]. The resulting metabolites can be excreted or, if chemically reactive, can cause cellular toxicity, including nephrotoxicity and carcinogenicity, through covalent modification of proteins and other macromolecules[2][3][4]. This metabolic pathway is particularly important for the activation and toxification of drugs, environmental pollutants, and naturally occurring compounds[2][3][4].

Other names
Cysteine conjugate β-lyaseCysteine-S-conjugate β-lyaseL-cysteine-S-conjugate thiol-lyase (deaminating; pyruvate-forming)Glutamine transaminase K/cysteine conjugate β-lyase
02

Mechanism of action

β-elimination of S-conjugated cysteine moieties resulting in formation of reactive intermediates; this can lead to drug bioactivation or toxification

03

Biological functions

Amino acid metabolism (non-physiological side reactions)Bioactivation (toxification) of halogenated hydrocarbons and certain drugsMetabolism of selenocysteine conjugates
04

Disease associations

Cancer (due to bioactivation of carcinogenic precursors)Nephrotoxicity (e.g., mediated by drug metabolites such as cisplatin and methazolamide)Toxicological relevance (especially for environmental pollutants like halogenated alkenes)
05

Safety considerations

Formation of toxic, reactive thiols or intermediates (e.g., nephrotoxicity, carcinogenicity)Potential for covalent binding of toxic metabolites to proteins, leading to tissue injury
06

Interacting drugs

Methazolamide

2 more in the full profile.

07

Biomarkers

Specific S-conjugated cysteine metabolites in urine and tissues can be monitored for target activity and drug-induced toxicity

Beyond the preview

Go deeper on Cysteine-S-conjugate beta-lyase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cysteine-S-conjugate beta-lyase.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call